A £15m legal claim over flammable cladding on a high-rise site in London has been paused pending a mediation procedure.

EMA’s human medicine committee recommends marketing approval for acoramidis for treatment of transthyretin amyloid cardiomyopathy: Berlin Monday, December 16, 2024, 13:00 Hrs [I ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the ...